Novel customizable and flexible single-use assembly solution
Hugh Purity New England's solution can utilize other vendors' components and can be implemented directly into any process.
Demand for single-use assembly solutions in the biopharma industry continues to increase, with the market expected to be worth $26.89 billion by 2025.
To help meet that demand, High Purity New England (HPNE), a supplier of biopharma equipment and process solutions for the biopharma industry, has created HPConnexx, a single-use assembly solution suitable for all areas of biopharmaceutical processing from discovery to fill-finish.
Manufactured in an ISO 7 Cleanroom, the solution can utilize other vendors' components and can be implemented directly into any process.
“The solution, and the support we deliver around it, is truly unique as it can be customized in any way the customer requires. It can be connected to any existing process at any scale and utilize any components regardless of inter-company connectivity," explained the company's CEO and founder, Mark Sitcoske.
There is no minimum order size for an assembly and lead times can be as short as weeks, compared with the industry standard of months.
The team at HPNE also provide full integrity and validation testing on its single-use assemblies.
Sitcoske added: “Single-use technologies can reduce the costs associated with infrastructure, save time by decreasing the need for cleaning and validation and negate the risk of cross contamination. However, not all single-use solutions are fully customizable, and many have lengthy lead times for installation. That is why we developed HPConnexx.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...